{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:16:19Z","timestamp":1780467379514,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":157,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100587","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T13:07:58Z","timestamp":1654693678000},"page":"100587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant"],"prefix":"10.1016","volume":"32","author":[{"given":"Ayumi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-2246","authenticated-orcid":false,"given":"Maki","family":"Tanioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Odaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2022.100587_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2022.100587_bib0002","unstructured":"Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare) https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/index.html [Accessed August 28, 2021]."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100587_bib0003","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/ijgc-2019-000384","article-title":"The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)","volume":"29","author":"Enomoto","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6330","key":"10.1016\/j.ctarc.2022.100587_bib0004","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"17","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.ctarc.2022.100587_bib0005","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100587_bib0006","doi-asserted-by":"crossref","unstructured":"Ricci A.D., Rizzo A., Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box? ESMO open (2020) 5(5):e001042 [PMID: 32994319 PMCID: PMC7526276 doi: 10.1136\/esmoopen-2020-001042].","DOI":"10.1136\/esmoopen-2020-001042"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100587_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jmedgenet-2017-104560","article-title":"The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium","volume":"55","author":"Moghadasi","year":"2018","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100587_bib0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13691-020-00449-9","article-title":"Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome","volume":"10","author":"Yoshihama","year":"2021","journal-title":"Int. Cancer Conf. J."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100587_bib0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"ACMG laboratory quality assurance committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"issue":"25","key":"10.1016\/j.ctarc.2022.100587_bib0010","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2022.100587_bib0011","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10106","key":"10.1016\/j.ctarc.2022.100587_bib0012","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"28","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ctarc.2022.100587_bib0013","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1021\/bi2003795","article-title":"Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition","volume":"50","author":"Coquelle","year":"2011","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100587_bib0014","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/bcr1826","article-title":"Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?","volume":"9","author":"Lovelock","year":"2007","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2022.100587_bib0015","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2022.100587_bib0016","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:33:50Z","timestamp":1762842830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":16,"alternative-id":["S2468294222000776"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100587","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100587"}}